Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Blinatumomab in R/R and MRD+ B-ALL
NCT04521231Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2021
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Jan 2021; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04521231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521231.